long-term effects of glp-1 receptor agonists liraglutide (GLP-1 agonist) – Efficacy and Adverse Glucagon-like Receptor-1 agonists for obesity:
Description
Smaller mechanistic studies have explored GLP-1 effects in specific inflammatory conditions
Clinical trials show weight loss averaging 15-17% of body weight over a year
p = 0.271)
DOI: 10.3390/nu11020247, Fujiwara, Y., Eguchi, S., Murayama, H., et al
Phase 3 TRIUMPH-4 (topline) In Lillys topline summary, the most common adverse events included nausea, diarrhoea, constipation and vomiting (typical of incretin-based therapies)
